mRNA-Expressionsanalyse von Leukämie-assoziierten Antigenen bei der Chronisch Myeloischen Leukämie
LicenseStandard (Fassung vom 03.05.2003)
Specific immunotherapies for CML patients might eliminate residual CML cells after therapy with imatinib or chemotherapy and might enhance a specific graft versus leukemia effect after allogeneic stem cell transplantation. In this paper the expression and functional aspects of tumor/leukemia-associated antigens (TAAs/LAAs) in CML was investigated. Several LAAs are expressed and are therefore candidate structures for specific immunotherapies: bcr-abl (100%), G250 (24%), hTERT (53%), MPP11 (91%), NEWREN60 (94%), PRAME (62%), Proteinase3 (71%), RHAMM/CD168 (83%) and WT1 (53%). The antigens BAGE, MAGEA1, SSX2 or NY-ESO-1 were not detectable. The expression varied according to the leukocyte subset and expression of RHAMM/CD168, Proteinase3 and PRAME was upregulated in higher stages. Quantitative expression of some TAAs/LAAs were correlated to the clinical course. In flow cytometry, CD34+ CML progenitor cells typed positive for HLA-molecules, but were defective for CD40, CD80, CD83 and CD86. Lack of costimulatory molecules might constitute a tumor escape mechanism of these cells. Peptide vaccination might be a promising approach to enhance such specific immune responses in CML.
Subject HeadingsChronisch-myeloische Leukämie [GND]
Leukemia, myeloid [MeSH]
Tumor escape [MeSH]